Teva Pharmaceutical Industries Limited
TEVANYSEHealthcare● Active
$34.19
$-0.24(-0.70%)
Market Cap$39.8B
P/E Ratio—
52W High$37.35
52W Low$14.99
Teva Pharmaceutical Industries Limited (TEVA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
TEVA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 29, 2026EPS Actual
$0.53
Est. $0.50 · +6.0%
Revenue
$3.98B
Est. $3.79B · +5.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 29, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 8-Quarter EPS Beat Streak
TEVA reports quarterly as a NYSE-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.00
Rev. $0.01B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.00
Rev. Est.$0.01B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 29, 2026 | $0.53 | — | — | — | $4.06B | — |
| ▲ Q2 FY2026 | Apr 29, 2026 | $0.50 | $0.53 | +6.0% | $3.98B | $3.79B | +5.1% |
| ▲ Q1 FY2026 | Jan 28, 2026 | $0.65 | $0.96 | +47.7% | $4.71B | $4.32B | +9.1% |
| ▲ Q4 FY2025 | Nov 5, 2025 | $0.68 | $0.78 | +14.7% | $4.48B | $4.45B | +0.6% |
| ▲ Q3 FY2025 | Jul 30, 2025 | $0.63 | $0.66 | +4.8% | $4.18B | $4.36B | -4.3% |
| ▲ Q2 FY2025 | May 7, 2025 | $0.47 | $0.52 | +10.6% | $3.89B | $4.38B | -11.2% |
| ▲ Q1 FY2025 | Jan 29, 2025 | $0.69 | $0.71 | +2.9% | $4.23B | $4.10B | +3.0% |
| ▲ Q4 FY2024 | Nov 6, 2024 | $0.65 | $0.69 | +6.2% | $4.33B | $4.12B | +5.2% |
Q3 FY2026
Jul 29, 2026
EPS Actual
—
EPS Est.
$0.53
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 29, 2026Beat
EPS Actual
$0.53
EPS Est.
$0.50
EPS Surpr.
+6.0%
Revenue
$3.98B
Q1 FY2026
Jan 28, 2026Beat
EPS Actual
$0.96
EPS Est.
$0.65
EPS Surpr.
+47.7%
Revenue
$4.71B
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
$0.78
EPS Est.
$0.68
EPS Surpr.
+14.7%
Revenue
$4.48B
Q3 FY2025
Jul 30, 2025Beat
EPS Actual
$0.66
EPS Est.
$0.63
EPS Surpr.
+4.8%
Revenue
$4.18B
Q2 FY2025
May 7, 2025Beat
EPS Actual
$0.52
EPS Est.
$0.47
EPS Surpr.
+10.6%
Revenue
$3.89B
Q1 FY2025
Jan 29, 2025Beat
EPS Actual
$0.71
EPS Est.
$0.69
EPS Surpr.
+2.9%
Revenue
$4.23B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
$0.69
EPS Est.
$0.65
EPS Surpr.
+6.2%
Revenue
$4.33B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.86 | $0.88 | $0.92 | 2 |
| Q3 FY2027 | $0.83 | $0.85 | $0.89 | 2 |
| Q2 FY2027 | $0.70 | $0.71 | $0.74 | 2 |
| Q1 FY2027 | $0.62 | $0.63 | $0.66 | 3 |
| Q4 FY2026 | $0.69 | $0.71 | $0.74 | 3 |
| Q3 FY2026 | $0.43 | $0.44 | $0.46 | 7 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $4.4B | $4.5B | $4.6B | 3 |
| Q3 FY2027 | $4.4B | $4.5B | $4.6B | 3 |
| Q2 FY2027 | $4.1B | $4.2B | $4.4B | 3 |
| Q1 FY2027 | $4.0B | $4.0B | $4.2B | 3 |
| Q4 FY2026 | $4.2B | $4.3B | $4.4B | 5 |
| Q3 FY2026 | $4.1B | $4.3B | $4.5B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 29, 2026 | +6.0% | $31.62 | $35.38 | +11.89% |
| ▲ Q1 FY2026 | Jan 28, 2026 | +47.7% | $32.53 | $33.21 | +2.09% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +14.7% | $20.46 | $24.60 | +20.23% |
| ▲ Q3 FY2025 | Jul 30, 2025 | +4.8% | $16.54 | $16.83 | +1.75% |
| ▲ Q2 FY2025 | May 7, 2025 | +10.6% | $16.12 | $17.60 | +9.18% |
| ▲ Q1 FY2025 | Jan 29, 2025 | +2.9% | $21.53 | $18.54 | -13.89% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +6.2% | $18.77 | $17.43 | -7.14% |
| ▲ Q3 FY2024 | Jul 31, 2024 | +7.0% | $16.41 | $17.43 | +6.22% |
Q2 FY2026+11.89%
Report Date
Apr 29, 2026
EPS Beat/Miss
+6.0%
Price Before
$31.62
Price After
$35.38
Q1 FY2026+2.09%
Report Date
Jan 28, 2026
EPS Beat/Miss
+47.7%
Price Before
$32.53
Price After
$33.21
Q4 FY2025+20.23%
Report Date
Nov 5, 2025
EPS Beat/Miss
+14.7%
Price Before
$20.46
Price After
$24.60
Q3 FY2025+1.75%
Report Date
Jul 30, 2025
EPS Beat/Miss
+4.8%
Price Before
$16.54
Price After
$16.83
Q2 FY2025+9.18%
Report Date
May 7, 2025
EPS Beat/Miss
+10.6%
Price Before
$16.12
Price After
$17.60
Q1 FY2025-13.89%
Report Date
Jan 29, 2025
EPS Beat/Miss
+2.9%
Price Before
$21.53
Price After
$18.54
Q4 FY2024-7.14%
Report Date
Nov 6, 2024
EPS Beat/Miss
+6.2%
Price Before
$18.77
Price After
$17.43
Q3 FY2024+6.22%
Report Date
Jul 31, 2024
EPS Beat/Miss
+7.0%
Price Before
$16.41
Price After
$17.43
Avg Beat Reaction+3.79%
Beat Rate8 / 8 quarters
Largest Move+20.23% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: TEVA ends December
Teva Pharmaceutical Industries Limited (TEVA) most recently reported earnings on April 29, 2026 for Q2 FY2026, posting EPS of $0.53 — beating the analyst consensus of $0.50 by +6.0%. TEVA has beaten EPS estimates for 8 consecutive quarters. The next TEVA earnings date is expected around September 1, 2026.
Each quarter, investors track TEVA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. TEVA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
TEVA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
TEVA earnings · 5 questionsTeva Pharmaceutical Industries Limited's next earnings report is expected around September 1, 2026. TEVA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; TEVA historically reports after market close (AMC).
TEVA earnings datewhen is TEVA earningsTEVA next earnings datewhen does TEVA report earningsTEVA earnings calendar
▸ Source: FMP · Teva Pharmaceutical Industries Limited SEC filings · US GAAP · Teva Pharmaceutical Industries Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026